Research output per year
Research output per year
Fingerprint
Dive into the research topics where Joachim Aerts is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
van Gulijk, M., Belderbos, B., Dumoulin, D., Cornelissen, R., Bezemer, K., Klaase, L., Dammeijer, F. & Aerts, J., 1 Apr 2023, In: International Journal of Cancer. 152, 7, p. 1438-1443 6 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile5 Downloads (Pure) -
Diagnostic performance of electronic nose technology in chronic lung allograft dysfunction
Wijbenga, N., Hoek, R. A. S., Mathot, B. J., Seghers, L., Moor, C. C., Aerts, J. G. J. V., Bos, D., Manintveld, O. C. & Hellemons, M. E., Feb 2023, In: Journal of Heart and Lung Transplantation. 42, 2, p. 236-245 10 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile10 Downloads (Pure) -
Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers
van Kooten, J. P., de Gooijer, C. J., von der Thüsen, J. H., Brandt-Kerkhof, A. R. M., Albers, A. G. J., Lahaye, M. J., Monkhorst, K., Burgers, J. A., Aerts, J. G. J. V., Verhoef, C. & Madsen, E. V. E., Mar 2023, In: European Journal of Surgical Oncology. 49, 3, p. 611-618 8 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab
Malmberg, R., Zietse, M., Dumoulin, D. W., Hendrikx, J. J. M. A., Aerts, J. G. J. V., van der Veldt, A. A. M., Koch, B. C. P., Sleijfer, S. & van Leeuwen, R. W. F., 1 Dec 2022, In: The Lancet Oncology. 23, 12, p. e552-e561Research output: Contribution to journal › Review article › Academic › peer-review
1 Citation (Scopus) -
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Kindler, H. L., Novello, S., Bearz, A., Ceresoli, G. L., Aerts, J. G. J. V., Spicer, J., Taylor, P., Nackaerts, K., Greystoke, A., Jennens, R., Calabrò, L., Burgers, J. A., Santoro, A., Cedrés, S., Serwatowski, P., Ponce, S., Van Meerbeeck, J. P., Nowak, A. K., Blumenschein, G., Siegel, J. M., & 7 others, Apr 2022, In: The Lancet Oncology. 23, 4, p. 540-552 13 p.Research output: Contribution to journal › Article › Academic › peer-review
4 Citations (Scopus)